Evidence map›Paper›PMID 34293915›Full record

Observational studyThe Journal of urology2021

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.

Charles J Ryan, Xuehua Ke, Marie-Hélène Lafeuille, Hela Romdhani, Frederic Kinkead, Patrick Lefebvre, Allison Petrilla, Zul Pulungan, Seung Kim, Denise M D'Andrea and 2 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Charles J RyanDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Xuehua KeJanssen Scientific Affairs, LLC, Horsham, Pennsylvania.
Marie-Hélène LafeuilleAnalysis Group, Inc., Montreal, Quebec, Canada.
Hela RomdhaniAnalysis Group, Inc., Montreal, Quebec, Canada.
Frederic KinkeadAnalysis Group, Inc., Montreal, Quebec, Canada.
Patrick LefebvreAnalysis Group, Inc., Montreal, Quebec, Canada.
Allison PetrillaAvalere Health, Washington, District of Columbia.
Zul PulunganAvalere Health, Washington, District of Columbia.
Seung KimAvalere Health, Washington, District of Columbia.
Denise M D'AndreaJanssen Scientific Affairs, LLC, Horsham, Pennsylvania.
Peter FrancisJanssen Pharmaceuticals, Inc., Raritan, New Jersey.
Stephen J FreedlandDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Prevea Health · USJanssen (United States) · USCedars-Sinai Medical Center · USJanssen Scientific Affairs (United States)University of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study provides a contemporary assessment of the treatment patterns, health care resource utilization (HRU) and costs among metastatic castration-sensitive prostate cancer (mCSPC) patients in the U.S. MATERIALS AND

methodsAdults with mCSPC were selected from Optum's de-identified Clinformatics® Data Mart Database (Commercial insurance/Medicare Advantage [COM/MA]; January 1, 2014-July 31, 2019) or Medicare Fee-for-Service (FFS; January 1, 2014-December 31, 2017). The index date was the first metastatic disease diagnosis date on/after the first prostate cancer diagnosis (without prior evidence of castration resistance). Patients were observed for 12 months pre-index (baseline) through their mCSPC period (from index until castration resistance or followup end). First-line (1L) mCSPC therapy was assessed during the mCSPC period; all-cause HRU and health plan-paid costs per-patient-per-year (PPPY) were measured during baseline and mCSPC periods.

resultsAmong 6,517 COM/MA and 13,324 Medicare-FFS mCSPC patients over ∼10 months (median mCSPC period), 38% and 48% remained untreated/deferred treatment, and 45% and 46% received 1L androgen deprivation therapy (ADT) monotherapy, respectively. 1L abiraterone acetate and docetaxel were used among 7% and 6% of COM/MA and 1% and 2% of Medicare-FFS patients, respectively. HRU increased from baseline to mCSPC period, resulting in increased health plan-paid costs from $21,201 to $108,767 in COM/MA and from $16,819 to $69,639 PPPY in Medicare-FFS.

conclusionsThis study highlights the limited use of newer therapies that improve survival in men with mCSPC in the U.S. HRU and costs increased substantially after onset of metastasis. Given the emergence of newer effective mCSPC therapies, further evaluation of future real-world mCSPC treatment patterns and outcomes is warranted.

Indexed as

AgedAged, 80 and overCohort StudiesHealth Care CostsHealth ResourcesHumansMaleNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantRetrospective StudiesUnited Stateshealth care costsneoplasm metastasis, castrationprocedures and techniques utilizationprostatic neoplasms

Identifiers

PMID34293915
PMCPMC8584208
OpenAlexW3183995494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.